Brokerages Set InfuSystem Holdings, Inc. (NYSE:INFU) PT at $13.50

Shares of InfuSystem Holdings, Inc. (NYSE:INFU) have received an average recommendation of “Buy” from the five analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, two have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $14.50.

INFU has been the topic of several recent research reports. Lake Street Capital began coverage on InfuSystem in a research report on Monday, September 22nd. They issued a “buy” rating and a $15.00 price objective on the stock. Roth Capital set a $14.00 target price on shares of InfuSystem and gave the company a “buy” rating in a report on Tuesday. Finally, Zacks Research lowered shares of InfuSystem from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th.

Insider Buying and Selling at InfuSystem

In other news, Director Scott Shuda sold 5,752 shares of InfuSystem stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $9.67, for a total transaction of $55,621.84. Following the completion of the transaction, the director directly owned 94,000 shares of the company’s stock, valued at $908,980. The trade was a 5.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 11.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On InfuSystem

A number of institutional investors have recently added to or reduced their stakes in the stock. ARS Investment Partners LLC acquired a new stake in InfuSystem in the 3rd quarter valued at $117,000. Brevan Howard Capital Management LP acquired a new stake in InfuSystem in the 2nd quarter valued at $228,000. Bank of America Corp DE grew its stake in InfuSystem by 19.4% in the 2nd quarter. Bank of America Corp DE now owns 17,994 shares of the company’s stock valued at $112,000 after acquiring an additional 2,924 shares during the period. Ameriprise Financial Inc. grew its stake in InfuSystem by 82.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 130,350 shares of the company’s stock valued at $813,000 after acquiring an additional 58,810 shares during the period. Finally, Jane Street Group LLC grew its stake in InfuSystem by 943.1% in the 2nd quarter. Jane Street Group LLC now owns 186,159 shares of the company’s stock valued at $1,162,000 after acquiring an additional 168,312 shares during the period. Institutional investors and hedge funds own 71.13% of the company’s stock.

InfuSystem Stock Performance

Shares of INFU stock opened at $9.46 on Friday. InfuSystem has a 52-week low of $4.61 and a 52-week high of $11.04. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50. The stock has a market cap of $193.23 million, a PE ratio of 157.69 and a beta of 1.79. The business has a 50-day simple moving average of $10.09 and a 200-day simple moving average of $7.63.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.